logo
Weight Loss Drugs Work – but Only if You Do These 3 Things

Weight Loss Drugs Work – but Only if You Do These 3 Things

WebMD4 days ago
July 18, 2025 – You know them by names like Ozempic and Wegovy, and for what they can do – help people lose weight. But if you're among the roughly 1 in 8 Americans who've tried GLP-1 drugs – including newer options like Zepbound and Mounjaro, which target more than one hormone – you could be at risk of nutrient deficiency, muscle loss, and even bone loss, unless you make diet and exercise part of the picture.
"Although GLP-1 medications are a major breakthrough in obesity management, lifestyle factors still matter," said JoAnn E. Manson, MD, a professor of medicine at Harvard Medical School. "Outcomes of patients on these medications are much better with attention to adequate protein intake, healthy diet, good hydration, and regular muscle-strengthening exercises to mitigate the loss of lean body mass."
Manson is a co-author of new guidelines to help, published in JAMA Internal Medicine, one set for doctors and another for patients. "These represent what we believe are the first systematic tools to implement lifestyle interventions alongside GLP-1 medications," said Farhad Mehrtash, MPH, a co-author of the guidelines and a graduate of the Harvard T.H. Chan School of Public Health.
Here's a three-pronged approach to make the most of modern weight loss medications.
1. Maintain Your Muscle
With any weight loss, including that with GLP-1s, you don't get to pick where you lose it. "Loss of muscle and lean body mass is common on these medications, on average about 25%," said Manson. Over time, that can lead to bone loss too, especially in older adults or those with sedentary lifestyles.
Eat plenty of protein, the guidelines say. Aim for 1 to 1.5 grams per kilogram (or about half a gram per pound) of body weight each day – or 20 to 30 grams per meal. That's slightly higher than the standard 15 to 30 grams per meal recommended for all adults.
Exercise is also critical. Start with an evaluation of where you are now, and slowly work up to 150 minutes of cardio (like walking) and two to three 30-minute strength sessions each week, the CDC's recommended activity level.
Don't just rely on your doctor to guide you. "Most doctors won't have the time to thoroughly go through your exercise history, current lifestyle, and any hurdles to beginning exercise," said Samuel Klein, MD, a professor of medicine and nutritional science at Washington University in St. Louis. "Work with a trainer or someone who is an expert in how to exercise."
Insurance might cover personal training (if a doctor prescribes it as part of a medically necessary treatment plan), but a better bet: Ask your health care provider if it offers a formal weight management program – many qualify for reimbursement.
2. Sidestep Side Effects
The right eating strategy can help offset potential digestive side effects, such as constipation, nausea, and heartburn. "I recommend smaller, more frequent meals, decreasing fat and salt intake, and chewing slowly so that you reduce the amount of bulk leaving your stomach," said Klein. That helps your gut better manage the slower-than-usual movement of food into your intestines caused by GLP-1s.
Staying hydrated helps keep things moving, too – and dehydration is a risk of these medications, which suppress thirst along with appetite. The guidelines encourage eight to 12 glasses of water a day, along with soups and water-rich fruits and vegetables like cucumbers and watermelon. Keep dehydrating drinks with things like alcohol and caffeine to a minimum.
3. Keep These Habits – Even Post-Meds
These medications are intended for long-term use, said Jody Dushay, MD, a co-author of the guidelines and assistant professor of medicine at Harvard Medical School. "That said, once people reach a weight loss plateau at the highest tolerated dose, then you move to the weight maintenance phase of treatment."
That could mean "lowering the dose, staying on the same dose but extending the number of days between injections, or, least commonly, a trial off medication," Dushay said.
In general, keeping weight off is notoriously difficult, but research suggests that the key to success comes down to one thing: consistency.
"Weight regain is highly individualized and depends on many factors," said Dushay. Chief among them is an "ongoing engagement in a healthy lifestyle."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sarepta falls after gene therapy maker pauses Elevidys shipments in US
Sarepta falls after gene therapy maker pauses Elevidys shipments in US

Yahoo

time15 minutes ago

  • Yahoo

Sarepta falls after gene therapy maker pauses Elevidys shipments in US

(Reuters) -Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States. The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but the company refused to do so and said it would continue making the treatment available to ambulatory patients. But Sarepta has now voluntarily and temporarily paused all shipments of the therapy, effective end of Tuesday. The company said the decision would allow it to respond to requests from the FDA and maintain a positive relationship with the agency. "Though Sarepta claims its pause in shipments was voluntary, we think the company moved preemptively — bracing for an inevitable FDA mandate to pull the drug," said H.C. Wainwright analyst Mitchell Kapoor. Shares of Sarepta fell 6.9% to $12.40 in early trading on Tuesday. "Sarepta's decision to comply was a capitulation after recognizing that the fight with the FDA was not winnable and that the agency would have strong-armed Sarepta into removing Elevidys with a formal demand," Kapoor added. Investor concerns regarding the use of the company's treatments have been heightened after the company on Friday disclosed that another patient who had received its experimental gene therapy died from acute liver failure, marking the third death this year. The company's shares have plummeted 89% so far this year. On Monday, Children's Hospital Los Angeles said it had paused usage of Elevidys in all patients with muscular dystrophy. The FDA's initial request had likely heightened the pressure on physicians to pause treatments, which could also have been a driving factor in Sarepta's decision, William Blair analyst Sami Corwin said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

HealthStream to Host Second Quarter 2025 Earnings Conference Call
HealthStream to Host Second Quarter 2025 Earnings Conference Call

Yahoo

time15 minutes ago

  • Yahoo

HealthStream to Host Second Quarter 2025 Earnings Conference Call

NASHVILLE, Tenn., July 22, 2025--(BUSINESS WIRE)--HealthStream, Inc. (Nasdaq: HSTM), a leading healthcare technology platform company for workforce solutions, announced today that it will host a conference call and webcast to discuss its second quarter 2025 financial results on Tuesday, August 5, 2025. The Company's financial results for the second quarter 2025 ended June 30, 2025 will be released after the routine time for the close of the market on Monday, August 4, 2025. HealthStream's second quarter 2025 earnings conference call will begin at 9:00 a.m. Eastern Time on Tuesday, August 5, 2025. Participants may access the conference call live via webcast using this LINK. To participate via telephone, please register in advance using this LINK. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. About HealthStream HealthStream (Nasdaq: HSTM) is the healthcare industry's largest ecosystem of platform-delivered workforce solutions that empowers healthcare professionals to do what they do best: deliver excellence in patient care. For more information, visit or call 615-301-3100. This press release contains forward-looking statements that involve risks and uncertainties regarding HealthStream. This information has been included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such results or events predicted in these statements may differ materially from actual future events or results. These forward-looking statements are based on a variety of assumptions that may not be realized, and which are subject to significant risks and uncertainties, including that the anticipated financial and strategic benefits of the acquisition may not be realized, as well as risks and uncertainties referenced from time to time in the Company's filings with the Securities and Exchange Commission. View source version on Contacts Mollie Condra, Investor Relations &CommunicationsHealthStream(615)-

AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom

Fast Company

time16 minutes ago

  • Fast Company

AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's U.S. clinical trial supply network and support ongoing investment in novel medicines. On Monday, AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the U.S. The U.S. accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market — the world's largest, worth $635 billion — before Trump's return to office. The move to scale up its U.S. footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the U.S. within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the U.S. to fall to what other countries pay. CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalize' with other countries effectively contributing more to research and development costs. 'The United States cannot build or carry the cost of R&D for the entire world,' he said. U.S. Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to 'get their act together' before any levies take effect. The company said that the timing and location of the announcement was linked to the U.S. policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said. PLEDGES The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility — the company's largest single manufacturing investment — will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the U.S. and has a global workforce of about 90,000. In January it scrapped plans to invest 450 million pounds ($607.1 million) in its vaccine manufacturing plant in northern England, citing a cut in government support. Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the U.S. The company declined to comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store